NO20052480L - Farmasoytiske sammensetninger med kontrollert frigjoring omfattende ladede polymerer. - Google Patents

Farmasoytiske sammensetninger med kontrollert frigjoring omfattende ladede polymerer.

Info

Publication number
NO20052480L
NO20052480L NO20052480A NO20052480A NO20052480L NO 20052480 L NO20052480 L NO 20052480L NO 20052480 A NO20052480 A NO 20052480A NO 20052480 A NO20052480 A NO 20052480A NO 20052480 L NO20052480 L NO 20052480L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
treating agent
controlled release
release pharmaceutical
charged polymers
Prior art date
Application number
NO20052480A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052480D0 (no
Inventor
Howard L Levine
William J Bologna
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/278,912 external-priority patent/US20030114394A1/en
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of NO20052480D0 publication Critical patent/NO20052480D0/no
Publication of NO20052480L publication Critical patent/NO20052480L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052480A 2002-10-24 2005-05-23 Farmasoytiske sammensetninger med kontrollert frigjoring omfattende ladede polymerer. NO20052480L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/278,912 US20030114394A1 (en) 2001-10-29 2002-10-24 Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US43850103P 2003-01-08 2003-01-08
PCT/EP2003/004316 WO2004037229A1 (en) 2002-10-24 2003-04-25 Extended, controlled release pharmaceutical compositions comprising charged polymers

Publications (2)

Publication Number Publication Date
NO20052480D0 NO20052480D0 (no) 2005-05-23
NO20052480L true NO20052480L (no) 2005-07-25

Family

ID=32179474

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052480A NO20052480L (no) 2002-10-24 2005-05-23 Farmasoytiske sammensetninger med kontrollert frigjoring omfattende ladede polymerer.

Country Status (23)

Country Link
EP (1) EP1556015B1 (pl)
JP (1) JP5204374B2 (pl)
KR (1) KR20050083802A (pl)
CN (2) CN101327326A (pl)
AR (1) AR039464A1 (pl)
AU (1) AU2003233066B2 (pl)
BR (1) BR0315576A (pl)
CA (1) CA2503383C (pl)
CO (1) CO5700711A2 (pl)
ES (1) ES2618300T3 (pl)
HR (1) HRP20050448A2 (pl)
MA (1) MA27493A1 (pl)
ME (2) ME00233B (pl)
MX (1) MXPA05004330A (pl)
NO (1) NO20052480L (pl)
NZ (1) NZ539512A (pl)
PE (2) PE20040323A1 (pl)
PL (1) PL376537A1 (pl)
RS (1) RS20050321A (pl)
RU (2) RU2366410C2 (pl)
TW (1) TW200406223A (pl)
WO (1) WO2004037229A1 (pl)
ZA (1) ZA200503133B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007014068A (es) * 2005-05-10 2008-02-07 Novartis Ag Composiciones farmaceuticas de liberacion modificada de famciclovir.
WO2017130208A1 (en) * 2016-01-29 2017-08-03 Faheem Hyder Pottoo Triple drug combination for treatment of status epilepticus and/or partial seizures and/or partial seizures with associated neurological disorders
CN119074731B (zh) * 2024-09-20 2026-03-20 湖南师范大学 盐酸达克罗宁在预防雌性小鼠下丘脑-垂体-卵巢轴损伤中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151286T1 (de) * 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
ATE113841T1 (de) * 1989-10-31 1994-11-15 Columbia Lab Inc Mittel zur feuchthaltung vaginalen gewebes.
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
ATE277640T1 (de) * 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
UA74168C2 (uk) * 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу

Also Published As

Publication number Publication date
CA2503383C (en) 2013-03-12
AU2003233066A1 (en) 2004-05-13
ES2618300T3 (es) 2017-06-21
MEP34108A (hr) 2011-02-10
CN101327326A (zh) 2008-12-24
MA27493A1 (fr) 2005-08-01
JP5204374B2 (ja) 2013-06-05
PE20081613A1 (es) 2008-11-15
WO2004037229A1 (en) 2004-05-06
RS20050321A (sr) 2007-08-03
NO20052480D0 (no) 2005-05-23
PE20040323A1 (es) 2004-06-10
JP2006506453A (ja) 2006-02-23
MXPA05004330A (es) 2005-08-02
ZA200503133B (en) 2006-12-27
RU2005115574A (ru) 2005-10-27
CO5700711A2 (es) 2006-11-30
TW200406223A (en) 2004-05-01
EP1556015B1 (en) 2017-02-22
EP1556015A1 (en) 2005-07-27
BR0315576A (pt) 2005-08-30
RU2009112072A (ru) 2010-10-10
KR20050083802A (ko) 2005-08-26
RU2366410C2 (ru) 2009-09-10
AU2003233066B2 (en) 2009-11-19
CN1703205B (zh) 2010-12-01
NZ539512A (en) 2009-03-31
AR039464A1 (es) 2005-02-23
HRP20050448A2 (en) 2005-12-31
ME00233B (me) 2011-05-10
CA2503383A1 (en) 2004-05-06
CN1703205A (zh) 2005-11-30
PL376537A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
BRPI0509366A (pt) método para remover potássio de um indivìduo animal, formulação farmacêutica, métodos para tratar uma doença e para determinar uma permeabilidade de casca a um ìon, composição farmacêutica, composição de núcleo-casca,e, método para sintetizar um polìmero de alfa-fluroacrilato
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
NO20084088L (no) Preparater og fremgangsmater for levering av aminofunksjonelle legemidler
MX265503B (es) Agente para el tratamiento del cabello que contiene una combinacion de polimeros.
NO982764L (no) Oppfinnelse og anordning for transdermal anordning for avgivelse av flurbiprofen
BRPI0416032A (pt) excipientes em veìculos de distribuição de fármacos
NO20053545L (no) Bindingsmidler som inhiberer myostatin.
ATE515949T1 (de) Süssware
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
NZ600257A (en) Device and method for delivery of two or more drug agents
MA27523A1 (fr) Formulation retard a liberation controlee
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
WO2006118937A3 (en) Concentration gradient profiles for control of agent release rates from polymer matrices
WO2005009417A8 (en) Composition and method for controlling drug delivery from silicone adhesive blends
MX2007010673A (es) Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
DE60331552D1 (de) Darreichungssysteme von wirkstoffen mit poly(ethylene-co(meth)akrylate, medizinische vorrichtung und verfahren
NO20023473L (no) Sammensetninger for levering av en kortisol antagonist
WO2010068862A3 (en) Zwitterionic polymers with therapeutic moieties
EA200970237A1 (ru) Применение тенектеплазы для лечения острого ишемического инсульта
NO20052894L (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
WO2008117268A3 (en) A drug delivery device for providing local analgesia, local anesthesia or nerve blockade
WO2006041911A3 (en) Device transdermal administration of drugs including acrylic polymers
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112022019846A2 (pt) Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application